Valuation: Revelation Biosciences, Inc.

Market Cap 4.49M 3.95M 3.67M 3.38M 6.33M 434M 6.45M 43.83M 17.09M 213M 16.87M 16.51M 736M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 4.49M 3.95M 3.67M 3.38M 6.33M 434M 6.45M 43.83M 17.09M 213M 16.87M 16.51M 736M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.21%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2020
Director of Finance/CFO 46 01/05/2020
Corporate Officer/Principal - 01/05/2020
Director TitleAgeSince
Chairman 58 03/06/2025
Director/Board Member 73 01/05/2020
Director/Board Member 62 01/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+20.71% - - 4.49M
+1.08%-6.74%-2.31%+10.45% 46.06B
+3.13%+2.34%+393.21%+605.08% 38.91B
+2.14%+4.98%+10.55%+65.45% 35.57B
+4.43%+0.25%+10.64%-9.17% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.29%-5.92% - - 16.61B
+14.71%+14.47%+26.81%+146.99% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
+1.82%-1.02%+5.46%-30.74% 12.81B
Average +2.26%-2.12%+56.08%+103.38% 26.52B
Weighted average by Cap. +1.92%-2.47%+74.11%+129.70%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Employees
9